Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression

Open access
Duvvuri, Umamaheswar, Shiwarski, Daniel J., Xiao, Dong, Bertrand, Carol, Huang, Xin, Edinger, Robert S., Rock, Jason R., Harfe, Brian D., Henson, Brian J., Kunzelmann, Karl, Schreiber, Rainer, Seethala, Raja S., Egloff, Ann Marie, Chen, Xing, Lui, Vivian W., Grandis, Jennifer R., Gollin, Susanne M.·2012·Cancer Research

Abstract

Frequent gene amplification of the receptor-activated calcium-dependent chloride channel TMEM16A (TAOS2 or ANO1) has been reported in several malignancies. However, its involvement in human tumorigenesis has not been previously studied. Here, we show a functional role for TMEM16A in tumor growth. We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which correlated with decreased overall survival in patients with SCCHN. TMEM16A overexpression significantly promoted anchorage-independent growth in vitro, and loss of TMEM16A resulted in inhibition of tumor growth both in vitro and in vivo. Mechanistically, TMEM16A-induced cancer cell proliferation and tumor growth were accompanied by an increase in extracellular signal–regulated kinase (ERK)1/2 activation and cyclin D1 induction. Pharmacologic inhibition of MEK/ERK and genetic inactivation of ERK1/2 (using siRNA and dominant-negative constructs) abrogated the growth effect of TMEM16A, indicating a role for mitogen-activated protein kinase (MAPK) activation in TMEM16A-mediated proliferation. In addition, a developmental small-molecule inhibitor of TMEM16A, T16A-inh01 (A01), abrogated tumor cell proliferation in vitro. Together, our findings provide a mechanistic analysis of the tumorigenic properties of TMEM16A, which represents a potentially novel therapeutic target. The development of small-molecule inhibitors against TMEM16A may be clinically relevant for treatment of human cancers, including SCCHN. Cancer Res; 72(13); 3270–81. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-0475-t

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 277

Metadata

Authors
Duvvuri, U., Shiwarski, D. J., Xiao, D., Bertrand, C., Huang, X., Edinger, R. S., Rock, J. R., Harfe, B. D., Henson, B. J., Kunzelmann, K., Schreiber, R., Seethala, R. S., Egloff, A. M., Chen, X., Lui, V. W., Grandis, J. R., & Gollin, S. M.
Venue
Cancer Research
Published
2012-07-01
Volume
72
Issue
13
Pages
3270-3281
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2116945755
Cited by
277
References
45
FWCI
9.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-0475-t
The paper
Duvvuri, U., Shiwarski, D. J., Xiao, D., Bertrand, C., Huang, X., Edinger, R. S., Rock, J. R., Harfe, B. D., Henson, B. J., Kunzelmann, K., Schreiber, R., Seethala, R. S., Egloff, A. M., Chen, X., Lui, V. W., Grandis, J. R., & Gollin, S. M. (2012). TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-0475-t

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.